Core Insights - Appili Therapeutics is actively seeking to expand its non-dilutive funding base through participation in the World Vaccine Congress Washington 2026, where executives will engage with global vaccine experts and government leaders [2][4]. Company Overview - Appili Therapeutics is a biopharmaceutical company focused on developing therapies for infectious diseases, with a mission to address life-threatening infections through a portfolio-driven approach [6]. - The company is advancing a diverse range of anti-infectives, including an FDA-approved metronidazole suspension, a vaccine candidate for biological threats, and a topical antiparasitic for disfiguring diseases [6]. Recent Collaborations and Funding - Appili has secured a US $40 million funding award from the National Institute of Allergy and Infectious Diseases to support the development of a fungal vaccine [8]. - The company is also advancing an in-licensed tularemia vaccine under a US $11.7 million award from the U.S. Air Force Academy [8]. - Additionally, Appili has launched LIKMEZ, a partnered liquid metronidazole product in the U.S., and is developing ATI-1801, a topical paromomycin product for leishmaniasis with demonstrated Phase 3 efficacy [8].

Core Insights - Appili Therapeutics is actively seeking new funding opportunities by participating in the World Vaccine Congress Washington 2026, where executives will engage with global vaccine experts and government leaders to expand their non-dilutive funding base [2][4]. Company Overview - Appili Therapeutics is a biopharmaceutical company focused on developing therapies for infectious diseases, with a mission to address life-threatening infections through a portfolio-driven approach [6]. - The company is advancing a range of anti-infectives, including an FDA-approved metronidazole suspension, a vaccine candidate for a biological weapon threat, and a topical antiparasitic for a disfiguring disease [6]. Funding and Collaborations - Appili has received a US $40 million funding award from the National Institute of Allergy and Infectious Diseases to support the development of a fungal vaccine [8]. - The company is also advancing an in-licensed tularemia vaccine under a US $11.7 million award from the U.S. Air Force Academy [8]. - Additionally, Appili has launched LIKMEZ, a partnered liquid metronidazole product in the U.S., and is developing ATI-1801, a topical paromomycin product for leishmaniasis with demonstrated Phase 3 efficacy [8].